Drop the altar completely! NEJM reports that hydroxychloroquine is not valid for COVID-19 patients!

2020 May 13 News /BioValleyBIOON / - A new study found no evidence that malaria has been widely promoted as the treatment of coronavirus infection Drug hydroxychloroquine any benefitresearchers recently published report, nearly 1,400 patients treated at the University of Columbia in New York, hydroxychloroquine does not reduce the risk of death or need ventilator on NewEnglandJournalofMedicineSome magazine editors and other doctors wrote in an editorial, although the study was observational, rather than strictly experimental, but it proved no clear evidence for thousands of COVID 19-patient It decided the case of the risks and benefits of the drug had to make to provide valuable informationSource: https: //cn.bing.comthey wrote, "it is disappointing that, in a pandemic few months, we have not received any stringent drug test results" Nevertheless, the new research "shows that this therapy is not a panacea." PresidentDonald Trump repeatedly urged the use of hydroxychloroquine, the drug now used to treat lupus
type a and a arthritis

It has potentially serious side effects, including changes in the way the heartbeat, it may lead to sudden deathUSFDAwarned that unless a formal study, do not use it for coronavirus infectionDoctorsColumbia University tracked the 565 who did not take the drug as well as 811 cases while taking the drug taking or not taking antibiotics patient of azithromycin A total of 180 patients requiring mechanical ventilation, 232 people were killed, but the drug does not seem to affect the probability of any one of them Patients taking hydroxychloroquine generally heavier than the other patient's condition, but widely accepted treatments into consideration this point, still do not see the effect of the drug began using it within two days after hospital admission Some critics said that earlier studies, treatment may be started too late, not have any effect The study was funded by the National Institutes of Health, and the Institute has conducted two experiments to compare hydroxychloroquine and placebo - establish the safety and effectiveness of the gold standard a study involving COVID-19 patients, another study aimed at understanding whether the drug helps prevent contact with health care workers infected with the virus Both trials were started in April a (Biovalley Bioon.com) References: Malariadrugshowsnobenefitinanothercoronavirusstudy JoshuaGelerisetal ObservationalStudyofHydroxychloroquineinHospitalizedPatients .NewEnglandJournalofMedicine.2020.DOI: 10.1056 / NEJMoa2012410